Chase Pharmaceuticals Corp.

SAN JOSE, Calif., May 30, 2024 /PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A seasoned healthcare finance executive and a current public company biotech Chief Financial Officer (CFO), Mr. Giacobello brings over 25 years of U.S. and global biopharmaceutical industry leadership experience to the role. "We are delighted to welcome Scott to our board. He will be an important addition as we grow and build our commercial organization for the potential launch of MDMA-assisted therapy should we receive FDA approval," said Jeff George, Chairman of the Lykos Board of Directors. "Scott's extensive financial and operational expertise, deep experience as a public company CFO of multiple biopharma companies, and his leadership roles in both fundraising and building out commercial organizations will be great assets to our board and leadership at Lykos." Mr. Giacobello is an industry veteran with more than 25 years of experience leading finance organizations. He is currently the CFO of Aadi Bioscience, Inc., a commercial-stage, Nasdaq-listed oncology biotech company and previously served as CFO of Nasdaq-listed GW Pharmaceuticals (acquired by Jazz Pharmaceuticals for $7.2 billion in 2021). At GW, he led the company's financial strategy, oversaw the build out of the commercial operations for Epidiolex, and helped lead more than $620 million in fundraising. Prior to GW, he served as CFO for Chase Pharmaceuticals Corporation, a clinical stage CNS biopharmaceutical company, until it was acquired by Allergan in 2016. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., including Vice President (VP) of Finance for global R&D, VP of Corporate Finance and VP of Internal Audit and Compliance. Mr. Giacobello's previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP, where he served as an auditor for a decade. He holds a bachelor's degree in business administration from the University of Notre Dame and is a certified public accountant. "This is an exciting time at Lykos as the team prepares for the potential commercialization of what may be the first psychedelic-assisted therapy if MDMA-assisted therapy is approved by the FDA," said Mr. Giacobello. "I am grateful for the opportunity to leverage my experience to support the company during this pivotal time as it grows and evolves to bring potential new treatment options to patients." With the appointment of Mr. Giacobello, the Lykos Board will now have nine members including five who are independent directors. Lykos Therapeutics At Lykos Therapeutics, a public benefit corporation (PBC) founded by MAPS, our mission is to transform mental healthcare. We're applying decades of evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a PBC, we are focused on delivering positive impact on our people, communities and society. To learn more visit us at and on LinkedIn, X, Instagram and Facebook.

LOS ANGELES, March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company. Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities. In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Mr. Delaney, continues to serve as the Executive Chairman and a member of the Board of directors and will assist with the leadership transition. The Board of Directors has initiated an executive search for a replacement CEO. "Supported by a strong and experienced team, Aadi continues to drive forward the development of FYARRO nab-sirolimus in solid tumor patients with TSC1 and TSC2 inactivating mutations, as well as continuing to serve patients with PEComa. Mr. Giacobello has played a critical role in crafting our corporate and financial strategy and I look forward to his continued leadership as we conduct a search for a permanent CEO," said Caley Castelein M.D., Chairman of the Board of Directors. Mr. Giacobello said, "I look forward to my continued work with the Aadi board and management team, executing on our mission of developing FYARRO for significant unmet needs in oncology. We have a well-defined strategy and a strong financial position and are enthusiastic about the opportunities that lie ahead." Prior to joining Aadi in 2021, Mr. Giacobello's background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies. He played a key role in the buildout of U.S. operations and commercial readiness in his role as CFO at GW Pharmaceuticals, leading the Company's financial strategy and raising more than $620 million ahead of their acquisition by Jazz Pharmaceuticals in 2021. He had previously served as the CFO of Chase Pharmaceuticals prior to their acquisition by Allergan, where he served in executive roles in corporate finance and global research and development. About Aadi Bioscience Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at and connect with us on Twitter and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Biosciences that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's current beliefs and expectations; anticipated future growth; the potential commercialization of FYARRO in the tumor agnostic oncology market; expectations regarding management performance following the leadership transition; and the Company's potential as a commercial precision oncology company. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those associated with uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for additional indications; the risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO; and risks related to collaborations with third-parties. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in Aadi's Quarterly Report on Form 10-Q filed November 9, 2022, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Marcy Graham [email protected] SOURCE Aadi Bioscience